EISAI AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS SIGNED GLOBAL RESEARCH COLLABORATION AGREEMENT TO CREATE NEW THERAPIES FOR NEURODEGENERATIVE DISEASES
TOKYO, December 14, 2022 /PRNewswire/ — Eisai Co., Ltd. (headquarters : TokyoCEO: Haruo Naito“Eisai”) announced today that Eisai and University of Washington School of Medicine Saint Louis have entered into a global research collaboration agreement aimed at creating potential new treatments for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). University of Washington …
